The Florida Society of Clinical Oncology leadership enjoyed seeing you at our Fall Session, a 2 day meeting designed for medical oncologists, hematologists, radiation oncologists, surgical oncology, pathologists, oncology nurses, nurse practitioners, pharmacists, physician assistants, oncology administrators, residents, and fellows that manage heath care for cancer patients. This conference provided an emphasis on multidisciplinary collaboration among all professional health care teams with dynamic educational tracks that focused on specific driven topics addressing the current and future changes in the landscape of cancer care.
The 2019 Fall meeting centered on the multi-disciplinary presentations and case studies in Colon Cancer and Multiple Myeloma which included the collaboration of top clinicians. Additional sessions included information on hot topics in advance provider practitioners, pharmacy, and administration.
Agenda
Exhibitors
Thank you for supporting the 2019 FLASCO Fall Session!
EXHIBIT INFO: We are expecting 150-175 attendees at the FLASCO Fall Session. Click here to view the 2019 Fall Session Attendee Roster.
EXHIBITORS
21st Century
AbbVie Pharmaceuticals
Acrotech Biopharma
Adaptive biotechnologies
Advanced Accelerator Applications, a Novartis company
Agios Pharmaceuticals
Alexion Pharmaceuticals
AMAG Pharmaceuticals
Amgen Oncology
Array Biopharma
Astellas Pharma
AstraZeneca
Bayer Healthcare
BeiGene
Boehringer Ingelheim
Briova Rx
Bristol-Myers Squibb
Caris Life Sciences
Celgene
Cleveland Clinic
Clovis Oncology
Coherus Biosciences
Daiichi Sankyo
Dova Pharmaceuticals
East Central Florida Cancer Control Collaborative
Eisai
EMD Serono
Equashield
EUSA Pharma
Exelixis
Florida Cancer Data System
Foundation Medicine
Genentech
Genomic Health
Gilead Sciences
Guardant Health
Helsinn Therapeutics
IBM Watson Healthcare
Immunomedics
Incyte
Ipsen Biopharmaceuticals
Johnson & Johnson
Kite Pharma
Kroger Specialty Pharmacy
Lilly Oncology
McKesson Specialty Health
Merck
Moffitt Cancer Center
NanoString Technologies
Natera
New Century Health
Novartis
Oncology Supply/ION Solutions
Pfizer Oncology
Pharmacyclics
Puma Biotechnology
Rigel Pharmaceuticals
Roche Diagnostics
Rx Vantage
Sanofi Genzyme
Seattle Genetics
Stemline
Sun Pharma
Surterra Wellness
Taiho Oncology
Takeda Oncology
Tempus
TESARO
Teva Pharmaceuticals
The Leukemia and Lymphoma Society
UF Health Cancer Center
Walgreens Specialty Pharmacy
Continuing Education
Accreditation and Credit Statements
Evaluation & Certificate of Attendance
- A link to the evaluation survey will be emailed to you post-program. Please complete this within the allotted time frame. If you do not receive a post-program email by 11/15/19, reach out to the FLASCO office.
- Your certificate of attendance will be emailed to you for download immediately after submission. Keep the certificate of attendance document for your files.
In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician: This activity has been approved for AMA PRA Category 1 Credit(s)TM.
Nurse/Advanced Nurse Practitioner: This activity has been approved for ANCC contact hours.
Pharmacist: This Application-based activity has been approved for ACPE contact hours.
Physician Assistant: NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society.
Disclosure Policy – The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content. MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.
Disclosure of Unlabeled Use – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.
Disclaimer – Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Poster Presentation
Abstracts for Poster Presentation
FLASCO Members Accepted Poster Abstracts
Ollie Anum, B.S., PharmD
Review on CTL019 and KTEC19, CART-cell Agents used for the Treatment of Large B-cell Lymphoma
Dharti Patel, Oak Hill Hospital
Mariya Fatakhova,Larkin University-College of Pharmacy
Mio Ezura, Nova Southeastern University
Nirali Vassa, Oak Hill Hospital
Ricardo Parrondo, MD, Mayo Clinic Florida
Accepted Industry Poster Abstracts
Rama Blaraman, MD, Florida Cancer Affiliates, Bristol-Myers Squibb
Heather Copher-Sweeney, PharmD, Bristol-Myers Squibb
Trevor McKibbin, PharmD, Pfizer Oncology
Jennifer Sibley, Bristol-Myers Squibb
Jeff Steinberg, PharmD, Pfizer Oncology
Jessica Unzaga, PharmD, BCPS, Baptist Health South, Pfizer Oncology
Josean Vargas-Maisonet, PharmD
Nichole Allen & Yingtao Zhang, MD, Merck
Hotel
Renaissance Orlando at SeaWorld
6677 Sea Harbor Drive, Orlando, Florida
1-407-351-5555
1-800-266-9432
Gallery
Powerpoints
| General Session | Innovative Solutions and Best Practices in Clinical Research | Howard “Skip” Burris III, MD, FACP, FASCO |
| General Session | Breast Cancer Management: Emphasis on Immunotherapy | Hope S. Rugo, MD |
|
Multidisciplinary |
Multiple Myeloma and AL Amyloidosis |
Raymond Comenzo, MD Emily Jonczak, MD |
| Pharmacy |
Lilit Smith, PharmD, MBA Marie Anne Louis-Jeune, PharmD, BCPS |
|
| Pharmacy | Updates in Immunotherapy & Rare Immunotherapy Toxicity Management: A case based approach | Jennifer Swank, PharmD |
| APP/Nurse/Navigator | Oncologic Emergencies | Lisa Welsh, MBA, PA-C |
| APP/Nurse/Navigator | Sexual Health in Oncology | Maray Salina, MSN, RN, NP-C |
| Administrator | Telemedicine | Bill Manzie, MBA |
| Lunch Presentation | The Benefits of Prescreening for Lung Cancer | Luis E. Raez, MD, FACP, FOCP |
| Lunch Presentation | Role of R2 in Previously Treated Follicular Lymphoma | Celeste Bello, MD, MSPH |
| Lunch Presentation | Using Huddles to Empower, Change, and Improve Employee Communication and Enhance Patient Care | Carie Colby |
| Multidisciplinary | Colon Cancer: A discussion regarding diagnosis and treatment for a patient under 50 | Mintallah Haider, MD with Panel of Experts |
| Pharmacy | Biosimilars: Beyond the Scientific Review | Jorge Garcia, PharmD, MS, MHA, MBA, FACHE |
| Pharmacy | Updates in Gastrointestinal Cancers | Anand Shah, Pharmd, BCOP, BCPS |
| Pharmacy | Navigating Your Way to Medication Assistance Program Success | Susan Downey, PharmD c/o Angelica Berni, PharmD |
| APP/Nurse/Navigator | USP 800: Beyond the Basics | Lilit Smith, PharmD, MBA |
| APP/Nurse/Navigator | Artificial Intelligence | Mehool Patel, MD, MBA, FACP |
| APP/Nurse/Navigator | Survivorship Care Planning: Best Practices |
Rick McDonough, MD Smitha Pabbathi, MD Karen Stephenson, DNP, MBA, APRN, OCN |
| Administrator | Challenges with Specialized Testing | Rise Marie Cleland |
| Administrator | Prior Authorization Burdens |
Rise Marie Cleland Andrew Hertler, MD, FACP |
